2021
DOI: 10.7150/ijms.53298
|View full text |Cite
|
Sign up to set email alerts
|

Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients

Abstract: Anemia, for which erythropoiesis-stimulating agents (ESAs) and iron supplements (ISs) are used as preventive measures, presents important difficulties for hemodialysis patients. Nevertheless, the number of physicians able to manage such medications appropriately is not keeping pace with the rapid increase of hemodialysis patients. Moreover, the high cost of ESAs imposes heavy burdens on medical insurance systems. An artificial-intelligence-supported anemia control system (AISACS) trained using administration d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…ML has demonstrated a pivotal role in estimating the onset of acute kidney injury [2][3][4][5] and the therapeutic responses of diabetic nephropathy [6] and IgA nephropathy [7]. In dialysis treatment, ML has also shown to be useful in the adjustment of the erythropoiesis-stimulating agent dosage for renal anemia [8][9][10][11], prediction of the occurrence of hypotension [12][13][14], and evaluation of fluid volume for patients undergoing dialysis [15]. In healthcare systems, ML has the potential to improve the selection of appropriate investigation and therapeutic processes, possibly resulting in improved prognosis in hemodialysis patients.…”
Section: Introductionmentioning
confidence: 99%
“…ML has demonstrated a pivotal role in estimating the onset of acute kidney injury [2][3][4][5] and the therapeutic responses of diabetic nephropathy [6] and IgA nephropathy [7]. In dialysis treatment, ML has also shown to be useful in the adjustment of the erythropoiesis-stimulating agent dosage for renal anemia [8][9][10][11], prediction of the occurrence of hypotension [12][13][14], and evaluation of fluid volume for patients undergoing dialysis [15]. In healthcare systems, ML has the potential to improve the selection of appropriate investigation and therapeutic processes, possibly resulting in improved prognosis in hemodialysis patients.…”
Section: Introductionmentioning
confidence: 99%